2.5 Billion People Threatened by This Disease: How We're Fighting Back

According to the WHO, 2.5 billion people are at risk for dengue fever, between 50 million and 100 million people contract the disease each year, and over a million people die from it each year.

For such a big health risk, you'd expect big plans to fight back. And science looks ready to deliver, with multiple approaches being used to help turn the tide.

In Brazil, where dengue fever is depressingly common (the highest incidence in the world), an intriguing pilot program has begun. In the lab, a gene is inserted into male mosquitoes that will kill them (although they are fed a temporary antidote that will keep them alive until their mission is complete); they're released into the world, mate, and pass on the gene to their offspring. The offspring die before adulthood, hopefully helping winnow down the mosquito population.

There's also another option: a dengue vaccine. Several companies are developing vaccines, chief among them best-in-class European big pharma Sanofi  (NYSE: SNY  ) . Sanofi has already completed a late-stage trial for its dengue vaccine, and the data look good (although we're still waiting to receive more data from another late-stage trial). And helping defeat this scourge could be big money for Sanofi, with its vaccine having the potential (if approved) to be a blockbuster drug.

In the video below, from Where The Money Is, the Motley Fool's investing show, health care analysts Michael Douglass and David Williamson discuss dengue, how we're fighting back, and Sanofi's exciting opportunity to do well by doing good.

Another huge opportunity to do well by doing good
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 3027044, ~/Articles/ArticleHandler.aspx, 7/22/2014 11:51:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement